Drug stocks a mixed bag;
Drug stocks were a mixed bag early Thursday as the broader market climbed ahead of a highly-anticipated meeting of the G20 member states to discuss how to tackle the on-going global economic crisis.
Drug stocks were mixed in early action Thursday with shares of Myriad Genetics Inc. climbing on news that it has signed a deal with Swedish drug conglomerate H. Lundbeck A/S for the European commercialization of Myriad's Alzheimer's drug candidate Flurizan.